The Increasing Proportion of Early-Stage Pancreatic Cancer between 2004–2013: A SEER Analysis

Abstract

Pancreatic cancer will become the second leading cause of cancer-related death in the United States by 2030. Survival improves when it is identified at an early-stage and resected. Increasing public attention and cross-section imaging may shift detection to earlier stages. We found a small total increase in the proportion of stage-I cancer relative to all stages and a significant increase compared to distant disease in the Surveillance, Epidemiology, and End Results (SEER) database. Despite this, our ability to screen and identify early-stage disease is still lacking. Additional research and population-based interventions are necessary to improve early detection.

Keywords:

• Pancreatic neoplasms
• pancreas
• digestive system neoplasms
• epidemiology
• public health

Disclosure statement

Sven P Oman: General payments/Minor Food and Beverage: Tenex Health Inc., Synergy Pharmaceuticals Inc.

Juan E Corral: Travel Grant: Abbvie, Inc. Minor Food and Beverage: Intercept Pharmaceuticals, Janssen Scientific, Boston Scientific Corporation and Cook Medical LLC.

John Stauffer: No conflicts of interest to disclose.

Massimo Raimondo: No conflicts of interest to disclose.

Kabir Mody: Consulting or Advisory Role: Celgene, Genentech, Eisai, AstraZeneca. Research Funding: Senhwa Biosciences, Merck Serono, MedImmune, AstraZeneca, Agios, Basilea, Taiho Pharmaceutical.

Michael B Wallace: Consulting: Virgo Inc, Cosmo/Aries Pharmaceuticals, Anx Robotica (2019), Covidien. Research grants: Fujifilm, Boston Scientific, Olympus, Medtronic, Ninepoint Medical, Cosmo/Aries Pharmaceuticals. Stock/Stock Options: Virgo Inc. Consulting on behalf of Mayo Clinic: GI Supply (2018), Endokey, Endostart, Boston Scientific. General payments/Minor Food and Beverage: Synergy Pharmaceuticals, Boston Scientific, Cook Medical.

Additional information

Funding

There was no funding for this work.